Abstract | BACKGROUND:
Hypertension is an important risk factor for myocardial infarction and stroke. Accumulating data support the association of blood pressure and impairment of fibrinolysis in hypertensive patients. Fibrinolysis plays a pivotal role in atherogenesis, but there are few studies that focus on evaluating the effect of calcium channel antagonists on fibrinolysis in hypertensive patients, and the results are controversial. The aim of this study was therefore to investigate the effects of cilnidipine on fibrinolysis in Chinese hypertensive patients. METHODS: RESULTS:
After treatment with cilnidipine for 8 weeks, plasma tPA antigen level increased significantly (from 12.12 +/- 6.77 ng/mL pre-treatment to 16.12 +/- 11.89 ng/mL post-treatment, p < 0.05), and the PAI-1 antigen level remained unaffected. There were no significant changes in plasma angiotensin II. Systolic and diastolic blood pressures were significantly decreased without changes in heart rate. CONCLUSIONS: These data suggest that in hypertensive patients, a population with impaired fibrinolysis, cilnidipine may improve the fibrinolytic balance, and that cilnidipine is effective in treating hypertension without causing reflex tachycardia.
|
Authors | Hong-Wei Tan, Li Li, Wei Zhang, Zhi-Yong Ma, Xue-Zhen Zhong, Jing-Jing Li, Ying Wang |
Journal | Clinical drug investigation
(Clin Drug Investig)
Vol. 25
Issue 12
Pg. 777-83
( 2005)
ISSN: 1173-2563 [Print] New Zealand |
PMID | 17532723
(Publication Type: Journal Article)
|